POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus PrednisoneMS Holleman, CA Uyl‐de Groot, IM Van Oort et al.|Value in Health|2022Cited by 0